Technology
Health
Pharmaceutical

Akari Therapeutics

$4.70
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.49 (12.01%) Today
+$0.13 (2.84%) After Hours

Why Robinhood?

You can buy or sell AKTX and other stocks, options, ETFs, and crypto commission-free!

About

Akari Therapeutics Plc ADR, also called Akari Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Coversin, is a second-generation complement inhibitor. Read More The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.

Employees
18
Headquarters
London, London & South East
Founded
2004
Market Cap
64.49M
Price-Earnings Ratio
Dividend Yield
Average Volume
506.80K
High Today
$5.17
Low Today
$4.30
Open Price
$4.30
Volume
1.43M
52 Week High
$9.20
52 Week Low
$1.56

Collections

Technology
Health
Pharmaceutical
Therapy
Medical
Biopharmaceutical
2015 IPO
UK

News

MarketWatchMar 14

Akari Therapeutics PLC ADR

Shares of Akari Therapeutics PLC more than doubled--soaring 145%--toward a 15-month high in very active morning trade Wednesday, enough to pace all the gainers on the Nasdaq exchange, after the company said it plans to commence trials in European and U.S. pediatric patients this year for its treatment of pediatric thrombotic microangiopathy.

2,232

Earnings

-$0.66
-$0.44
-$0.22
$0.00
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
Expected Mar 26, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.